Kalyan Roy: Hematopoietic Stem Cell Transplantation in Thalassaemia
Kalyan Roy, Transfusion Medicine Specialist at Square Hospitals LTD, shared a post on LinkedIn:
“Hematopoietic Stem Cell Transplantation (HSCT) in Thalassaemia
A Potentially Curative Therapy for Transfusion-Dependent Patients
For decades, treatment of severe thalassaemia mainly depended on:
- Lifelong blood transfusions
- Iron chelation therapy
- Continuous medical monitoring
Today, Hematopoietic Stem Cell Transplantation (HSCT) remains the most established curative treatment for severe thalassaemia.
What is HSCT?
HSCT is a procedure in which:Diseased or defective bone marrow is replaced with healthy hematopoietic stem cells.
The goal is to restore:
- Normal red blood cell production
- Functional hemoglobin synthesis
- Transfusion independence
Who May Benefit?
- β-thalassaemia major
- Transfusion-dependent thalassaemia patients
Best outcomes are generally seen in:
- Younger patients
- Patients with minimal organ damage
- HLA-matched sibling donors
- Early transplantation before severe iron overload complications
Sources of Stem Cells
Stem cells may be obtained from:
- Bone marrow
- Peripheral blood stem cells
- Umbilical cord blood
How Does HSCT Work?
- Step 1 — Pre-Transplant Evaluation
- Step 2 — Conditioning Therapy
Chemotherapy is administered to suppress diseased marrow and prepare the body for transplantation. - Step 3 — Stem Cell Infusion
Healthy donor stem cells are infused intravenously.
These cells migrate to the bone marrow and begin producing healthy blood cells. - Step 4 — Engraftment and Recovery
Over time:
Donor stem cells establish normal hematopoiesis.
Possible Complications
Although HSCT offers curative potential, it remains a complex procedure.
Possible complications include:
- Graft-versus-host disease (GVHD)
- Severe infections
- Graft failure
- Organ toxicity
- Infertility risk
- Transplant-related mortality
Factors Affecting Outcome
Transplant success depends on:
- Age at transplantation
- Degree of iron overload
- Liver status
- Donor compatibility
- Infection control
- Overall clinical condition
Early transplantation generally provides better outcomes.
HSCT vs Lifelong Transfusion
- Conventional therapy
- Regular transfusions
- Iron chelation
- Long-term supportive care
But:
Lifelong dependence continues.
- HSCT
- Potential cure
- Possible transfusion independence
- Reduced long-term iron overload
However:
Significant procedural risks exist.
Final Reflection
For selected thalassaemia patients, it offers the possibility of:
- Cure
- Freedom from lifelong transfusions
- Improved long-term quality of life.”
Other posts featuring Kalyan Roy on Hemostasis Today.
-
Oct 20, 2026, 16:51Suzan Nakasendwa: A Growing Stroke Challenge in Uganda
-
Oct 20, 2026, 16:38Steve Moon: How Does Smoking Cessation Duration Affect Ischemic Stroke Risk
-
Oct 20, 2026, 16:25Cedrice Mentor: Reducing Platelet Wastage Through Cold Storage
-
Oct 20, 2026, 16:09Thirunavukkarasu Angappan: Can a Purified Fibrinogen Concentrate Replace Cryoprecipitate
-
Oct 20, 2026, 16:01Kalyan Roy: Platelet Conservation Through Evidence-Based Transfusion Practice
-
Oct 20, 2026, 15:28Stacy E. Croteau: 33 Countries, One Mission – Better Bleeding Disorder Care
-
Oct 20, 2026, 15:19Teresa Barnes: What Does a Pulmonary Embolism Mean for Jalen Hurts?
-
Oct 20, 2026, 15:04Laura S.: Could Speaking Up Prevent Maternal Deaths from Thrombosis?
-
Oct 20, 2026, 14:44Pete Stibbs: VTE in Professional Athletes – When Fitness Is Not Enough